The global ulcerative colitis therapeutics market is projected to be worth USD 7.2 billion in 2025 and is expected to expand at a CAGR of 5.1%, reaching USD 11.9 billion by 2035, according to Fact.MR. Ulcerative colitis is a chronic form of inflammatory bowel disease (IBD) characterized by inflammation and ulceration in the colon and rectum.

In 2024, the market experienced notable growth, driven by a rising prevalence of IBD and the increasing adoption of biologics and advanced small-molecule therapies. Enhanced research and development efforts have led to the emergence of more targeted treatment options, significantly improving outcomes for patients with moderate to severe forms of the disease.

Therapy for ulcerative colitis has two basic objectives. The first is to reduce symptom severity and improve patient comfort, while also promoting gut repair. The second goal is to prevent further flare-ups. The goal of treatment is to reduce and control the disease's indications and symptoms.

The global ulcerative colitis therapeutics market is primarily driven by an increase in the incidence of inflammatory bowel diseases, increase in ulcerative colitis cases, and development of ulcerative colitis-specific medications by a large number of key companies.

Winning Strategy:

Key market players are focusing on the development of novel treatments for severe conditions of ulcerative colitis. Companies are involved in the development of novel drugs for the treatment of ulcerative colitis.

To enter into new markets and obtain high market share, key firms are focusing their efforts on product expansions and the development of innovative therapies, particularly in emerging economies. Alliances are being formed regularly to diversify product portfolios and boost market share.

For instance,

·       In 2019, Abbvie Company finalized the acquisition of Allergan, allowing it to expand its pharmaceutical range and provide patients with more advanced therapies. Allergen created a monoclonal antibody known as brazikumab, which is used to treat ulcerative colitis and Crohn's disease.

·       In April 2021, Arena Pharmaceuticals, Inc. started a phase II clinical trial to see if oral etrasimod is an effective therapy for adults with moderately active ulcerative colitis.

Key Companies Profiled-

Abbott Laboratories, Inc.; AstraZeneca PLC; Avaxia Biologics, Inc.; BioLineRx Ltd.; Astellas Pharma, Inc.; Cosmo Pharmaceuticals NV; AbbVie, Inc.; Amgen, Inc.

Industry News-

In May 2021, The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Zeposia (ozanimod) for the treatment of individuals with moderately to highly active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).

Old Source: https://www.globalbankingandfinance.com/ulcerative-colitis-therapeutics-market-to-reach-us-7-9-bn-by-2027-key-growth-drivers-and-market-insights